(inflation factor 7 l ¼ 1.02 and 1.05 in UK-GWA and US-GWA, respectively, based on the 90% least significant SNPs; Supplementary  Fig. 1b ), thereby excluding significant hidden population substructure or differential genotype calling. Using standard methods and data from both studies, we derived joint odds ratios (ORs) and confidence intervals for each SNP and associated P values.
To identify true risk alleles among the 34 SNPs showing evidence of an association at P o 10 À5 , we conducted replication in three casecontrol series involving a total of 5,498 individuals that passed quality control (French series: 1,392 cases, 1,602 controls; German series: 504 cases, 573 controls; Swedish series: 649 cases, 778 controls). We satisfactorily genotyped 31 of the 34 SNPs in all series. In the French series, rs9656979 and rs7257116 were not genotyped. However, an association between these SNPs and glioma risk was not supported in either the German or Swedish series (Supplementary Table 1) . Although rs7300686 was not typed in the German or Swedish series, an association with risk was not supported in the French series (Supplementary Table 1) . Hence, failure to genotype all additional series for the three SNPs has not affected study findings. Across the five data series, there was a significant association between rs7124728 and glioma risk, but this was not supported in the three replication series (P 4 0.1). rs4944840 maps 57 kb from rs7124728 and both SNPs are in strong linkage disequilibrium (LD; D¢ ¼ 0.89, r 2 ¼ 0.71). No association between rs4944840 and glioma risk was seen in either GWA study (P ¼ 0.13 UK-GWA, P ¼ 0.03 US-GWA). There was a significant difference in MAF of rs7124728 between both GWA cases and replication cases but not between controls, suggesting a genotyping error with the Illumina610-Quad BeadChip.
Excluding rs7124728, in the combined analyses, 14 of the 31 SNPs representing five genomic regions satisfied an accepted threshold for genome-wide statistical significance (that is, P o 5 Â 10 À7 ; Table 1 and Supplementary Table 1) . Under a fixed-effects model, the strongest signal was attained at rs4295627 (OR ¼ 1.36, 95% CI: 1.29-1.43; P ¼ 2.34 Â 10 À18 ), which localizes to 8q24.21 (130,754,639 bp; Fig. 2 and Table 1 ). There was, however, evidence of between-study heterogeneity (P het ¼ 0.01) ascribable to the association being modest in the Swedish series. Under a random-effects model, the OR was 1.36 (95% CI: 1.19-1.58; P ¼ 2.01 Â 10 À5 ) using all data and 1.45 (95% CI: 1.32-1.57; P ¼ 1.02 Â 10 À8 ) excluding the Swedish study. rs4295627 maps to intron 3 of CCDC26, encoding a retinoic acid modulator of differentiation and death 8 . Retinoic acid induces caspase-8 transcription through phosphorylation of CREB and increases apoptosis induced by death stimuli in neuroblastoma cells 9 and in glioblastoma cells with downregulation of telomerase activity 10 . Some evidence suggests a second 8q24. 21 Figure 1 Subjects and single-SNP exclusion schema for genome-wide association studies. There was also an increasing trend in OR with an increasing number of risk alleles (P ¼ 2.67 Â 10 À13 ) and the frequency of the two common haplotypes differed between cases and controls (Supplementary Table 2 ). When we imputed 8q24.21 genotypes using genome-wide data, rs1077236, mapping to 130,709,683 bp, provided a marginally better association signal than rs4295627 (P ¼ 2.75 Â 10 À9 and 1.60 Â 10 À8 , respectively). Hence, the possibility remains that rs4295627 and rs891835, although only weakly associated, are in LD with one or more causal variants in this region.
Variation at 8q24.21 has been implicated in colorectal 11 , breast 12 , prostate 6 and bladder cancer risk 13 . The genomic regions underlying these associations map to the 128-to 129-Mb interval, distinct from the glioma signal. Closer to the 8q24.21 glioma signal is rs987525, a risk factor for cleft lip 14 . Notably, nonsyndromic cleft lip has been reported to be a risk factor for PBT 15 . Although rs987525 maps 740 kb centromeric to rs4295627 and LD between rs987525 and rs4295627 is weak (D¢ ¼ 0.46, r 2 ¼ 0.01), it is possible that these SNPs define a common disease locus.
The second strongest evidence for an association was for rs2736100 (OR ¼ 1.27, 95% CI: 1.19-1.37; P ¼ 1.50 Â 10 À17 ) mapping to 5p15.33, which localizes to intron 2 of TERT (1,339,516 bp; Fig. 2 and Table 1 ). TERT is the reverse transcriptase component of telomerase, essential for telomerase activity in maintaining telomeres and cell immortalization. Although 5p15.33 copy number change is uncommon in glioblastoma multiforme (GBM; Supplementary Fig. 2a ), TERT expression correlates with glioma grade and prognosis 16 . Several lines of evidence raise the possibility of a second locus defined by rs2853676, which also maps to intron 2 of TERT (1, Table 2 ). Recent data has implicated variation at 5p15.33 (TERT-CLPTM1L) defined by rs2736098 with risk of multiple tumor types 17 . As LD between rs2736098 and both rs2736100 and rs2853676 is poor (D¢ ¼ 0.48 and r 2 ¼ 0.11 and D¢ ¼ 0.28 and r 2 ¼ 0.02 in HapMap and GWA scan, respectively), whether the 5p15.33 association with glioma is the same remains to be established. The third strongest evidence for an association was for rs4977756 (OR ¼ 1.24, 95% CI: 1.19-1.30; P ¼ 7.24 Â 10 À15 ), mapping 59 kb telomeric to CDKN2B (22,058,652 bp; Fig. 2 and Table 1 ) within a 122-kb region of LD at 9p21.3. This region encompasses the CDKN2A-CDKN2B tumor suppressor genes. CDKN2A encodes p16(INK4A) a negative regulator of cyclin-dependent kinases and p14(ARF1), an activator of p53. CDKN2A-CDKN2B has an established role in glioma, with homozygous deletion in CDKN2A detectable in B50% of tumors 18, 19 and loss of expression linked to poor prognosis 16 . Furthermore, germline mutation of CDKN2A-CDKN2B causes the melanoma-astrocytoma syndrome 20, 21 . Regulation of p16/p14ARF is important for sensitivity to ionizing radiation, the only environmental factor strongly linked to gliomagenesis 22 . These data provide evidence that common variation in addition to rare mutations in CDKN2A-CDKN2B contributes to glioma predisposition.
A 68-kb core region of 9p21.3 incorporating the association signal influences risk of type 2 diabetes (T2D) 23 and coronary heart disease (CHD) 24 . rs564398, a risk factor for T2D and CHD, is in LD with rs4977756 (D¢ ¼ 0.77, r 2 ¼ 0.50). A possible explanation for a common etiology is that these variants affect determination of birth weight, linked as a risk factor to all three diseases [25] [26] [27] .
The fourth strongest evidence for an association was for rs6010620 (OR ¼ Fig. 2a ). RTEL1 maintains genomic stability directly by suppressing homologous recombination 28 . These data, coupled with the role of TERT in glioma, make RTEL1 an attractive candidate for the 20q13.33 association but do not preclude the association being through variation in other genes mapping to the region, such as TNFRSF6B, whose expression correlates with glioma grade 29 .
The fifth-strongest signal was at rs498872 (OR ¼ 1.18, 95% CI: 1.13-1.24; P ¼ 1.07 Â 10 À8 ), which maps to the 5¢-UTR of PHLDB1 within a 101-kb LD block on 11q23.3 (117982577 bp; Fig. 2 and Table 1 ). There was, however, evidence of between-study heterogeneity (P het ¼ 0.04). Under a random-effects model, the combined OR was 1.16 (95% CI: 1.05-1.28; P ¼ 2.24 Â 10 À3 ). Most of this heterogeneity could be ascribed to the German series; excluding this, the OR was 1.22 (95% CI: 1.16-1.28; P ¼ 2.56 Â 10 À10 , P het ¼ 0.40). Although there is no direct evidence for a role of PHLDB1, 11q23.3 is commonly deleted in neuroblastoma 30 .
We analyzed the association between SNP genotypes and risk of tumors of glial origin, GBM and astrocytic lineage. There was evidence that GBMs have a different risk profile, notably with respect to rs4295627, rs498872 and rs2736100 (Supplementary Table 3) . However, because of study heterogeneity, we cannot exclude the possibility that the variants do not influence the risk of developing a specific histological form of glioma without central histopathological review.
We only found evidence of interactive effects between 8q24.21 SNPs (Supplementary Table 4 ). For all other pairwise combinations, each locus had an independent role in glioma (P interaction 4 0.10). Glioma risk increases with increasing numbers of variant alleles for the five loci (OR per-allele ¼ 1.31, 95% CI: 1.26-1.36; P ¼ 1.39 Â 10 À74 ; Fig. 3 and Supplementary Table 5 ). Individuals with eight or more risk alleles have an approximately fourfold increase in glioma risk compared to those with a median number of risk alleles. These ORs may be underestimates because the additive model assumes equal weighting across SNPs. We estimate that the five loci we have identified account for B7-14% of the excess familial risk of glioma (assuming naïve multiplicative or additive models and an overall familial relative risk of 2.1). However, we acknowledge that the present data provide only crude estimates of the effect on susceptibility attributable to variation at the loci, as the effect of the actual common causal variant responsible for the association will typically be larger.
To investigate the basis of causality for each of the five associations, we interrogated HapMap to identify nonsynonymous SNPs (nsSNPs) correlated with the most strongly associated SNP signals. The strongest LD was between rs6010620 and nsSNP rs3848668 (D¢ ¼ 1.0, r 2 ¼ 0.05). Although HapMap is not comprehensive, these data suggest the associations identified are probably mediated through LD with sequence changes that influence expression rather than protein sequence or through LD with low-frequency variants not catalogued. We searched for cis-acting regulatory effects of SNPs on nearby genes in lymphoblastoid cell lines and normal brain tissue using publicly available data. Although we did not identify any significant genotype-expression Fig. 2b ), this does not exclude subtle effects or the possibility that the variants exert effects through untested transactivation of genes. Our findings show that common variants influence glioma risk and highlight the importance of variation in genes encoding components of the CDKN2A-CDK4 signaling pathway in glioma. Moreover, this pathway, elucidated through the extended interaction network of CDKN2A, incorporates TERT (through mutual interaction with HSP90) and other genes (including CCDC26) we have identified as risk factors.
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Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website. and BONFOR. In Sweden, the collection of samples from the Northern Sweden Health of disease study were collected with support from Umeå University Hospital and NIH funded part of GLIOGENE collection (R01 CA119215). B.M. was supported by Acta Oncologica Foundation as a research fellow at Royal Swedish Academy of Science. In the UK we acknowledge NHS funding to the NIHR Biomedical Research Centre. The UK-GWA study made use of genotyping data on the 1958 Birth Cohort. Genotyping data on controls was generated and generously supplied to us by P. Deloukas (Wellcome Trust Sanger Institute). A full list of the investigators who contributed to the generation of the data are available from http://www.wtccc.org.uk. The US-GWA study made use of control genotypes from the CGEMS prostate and breast cancer studies. A full list of the investigators who contributed to the generation of the data are available from http://cgems.cancer.gov/. The results published here are in whole or part based upon data generated by The Cancer Genome Atlas pilot project established by the National Cancer Institute and National Human Genome Research Institute. Information about TCGA and the investigators and institutions that constitute the TCGA research network can be found at http://cancergenome.nih.gov. Finally, we are grateful to all the study subjects for their participation. We also thank the clinicians and other hospital staff, cancer registries and study staff who contributed to the blood sample and data collection for this study. Cases with previous brain tumors were excluded. To minimize population stratification, cases with self-reported non-western-European ancestry were excluded from the present study. Individuals from the 1958 Birth Cohort served as source of controls 4 .
AUTHOR CONTRIBUTIONS
US-GWA study. The US study was based on 1,247 cases (768 male, 479 female; mean age 47 years; s.d. Ethics. Collection of blood samples and clinico-pathological information from case and control subjects was undertaken with informed consent and relevant ethical review board approval in accordance with the tenets of the Declaration of Helsinki.
Genotyping. DNA was extracted from samples using conventional methodologies and quantified using PicoGreen (Invitrogen). Genotyping of both GWA studies was conducted by Illumina Service laboratory using the Illumina Infinium Human610-Quad BeadChips according to Illumina protocols. DNA samples with GenCall scores o0.25 at any locus were considered 'no calls' . To ensure quality of genotyping, a series of duplicate samples was genotyped in the same batches.
Intensity data from arrays was imported into Illumina's BeadStudio clustering and calling software application. For the small subset of loci that were not clustered properly by the automated algorithm, the data were reviewed to identify loci that needed to be removed, manually edited or left unchanged. Clustered SNPs were evaluated using the metrics listed in the SNP Table of the BeadStudio software. These metrics are based on all samples for each locus and thus provide overall performance information for each locus. To identify loci potentially needing to be edited or removed, each quality metric column in the SNP table was sequentially sorted. Metrics used for identifying poorly or incorrectly clustered data included intensity, cluster separation, position of each cluster (AA, AB, BB), Hardy-Weinberg equilibrium, call frequency and variation of cluster width. The reproducibility of control samples on each plate as well as replicates were also used to identify misclustered loci. Although not all cluster plots were assessed, B10% of the lowest performing loci were examined. Of these 10%, B20% were edited or annotated (to indicate loci with nearby polymorphisms or hemizygous deletions) and B2% were excluded. Review of data was conducted by a second individual to determine if any metrics were missed or if further editing was required. Overall, this process provided substantially increased genotyping accuracy.
Subsequent genotyping of SNPs was conducted using either competitive allele-specific PCR KASPar chemistry (KBiosciences) or single-base primer extension chemistry MALDI-TOF MS detection (Sequenom). All primers and probes used are available on request. Genotyping quality control was further evaluated through inclusion of duplicate DNA samples in SNP assays. For all SNP assays, 499% concordant results were obtained. Samples having SNP call rates o90% were excluded from the analysis.
Statistical analysis. Statistical analyses were undertaken using R (v2.6), STATA (v8; State College, Texas, US) and PLINK (v1.05) 33 software. All reported P values are two-sided. Genotype data were used to search for duplicates and closely related individuals among all samples in each of the GWA studies. Identity-by-state (IBS) values were calculated for each pair of individuals, and for any pair with allele sharing of 480%, the sample generating the lowest call rate was removed from further analysis. To identify individuals who might have non-Western European ancestry, we merged our case and control data with the 60 western European (CEU), 60 Nigerian (YRI), 90 Japanese (JPT) and 90 Han Chinese (CHB) individuals from the HapMap Project. For each pair of individuals, we calculated genome-wide IBS distances on markers shared between HapMap and our SNP panel and used these as dissimilarity measures upon which to perform principal component analysis. The first two principal components for each individual were plotted and any individual not present in the main CEU cluster (that is, outside 5% from cluster centroids) was excluded from subsequent analyses.
In the UK-GWA study, genotyped samples were excluded from analyses due to non-CEU ancestry (n ¼ 3). In the US-GWA study, genotyped samples were excluded from analyses for the following reasons: relatedness (n ¼ 2) and non-CEU ancestry (n ¼ 23).
The adequacy of the case-control matching and possibility of differential genotyping of cases and controls were formally evaluated using quantilequantile plots of test statistics. Deviation of the genotype frequencies in the controls from those expected under Hardy-Weinberg equilibrium (HWE) was assessed by a w 2 test or Fisher's exact test where an expected cell count was o5.
The association between each SNP and risk of glioma was assessed by the Cochran-Armitage trend test. Odds ratios and associated 95% CIs were calculated by unconditional logistic regression. Relationships between multiple SNPs showing association with glioma risk in the same region were investigated using logistic regression analysis, and the impact of additional SNPs from the same region was assessed by a likelihood-ratio test.
The combined effect of each pair of risk locus was investigated by logistic regression modeling with evidence for interactive effects between SNPs assessed by a likelihood ratio test. The OR and trend test for increasing numbers of deleterious alleles was estimated by counting two for a homozygote and one for a heterozygote.
Meta-analysis was conducted using standard methods based on weighted average of study-specific estimates of the ORs, using inverse variance weights. Cochran's Q statistic to test for heterogeneity and the I 2 statistic to quantify the proportion of the total variation due to heterogeneity were calculated. The sibling relative risk attributable to a given SNP was calculated using the following formula: 
where p is the population frequency of the minor allele, q ¼ 1 À p, and r 1 and r 2 are the relative risks (estimated as OR) for heterozygotes and rare homozygotes relative to common homozygotes. Assuming a multiplicative interaction the proportion of the familial risk attributable to a SNP was calculated as log(l * )/log(l 0 ), where l 0 is the overall familial relative risk estimated from epidemiological studies, assumed to be 2.1 (ref.
2). A naïve estimation of the contribution of all of the loci identified to the excess familial risk of glioma under an additive model was calculated using the following formula:
OR per allele À 1 2ðl 0 À 1Þ ð2Þ
Bioinformatics. LD metrics between SNPs reported in HapMap were based on Data Release 2/phaseIII Feb09 on NCBI B35 assembly, dbSNPb125, except for between rs2736098 and rs2736100 and rs2853676 which were only available in Data Release 23a/phaseII March08. We used Haploview software (v3.2) to infer the LD structure of the genome in the regions containing loci associated with glioma risk. Prediction of the untyped SNP in the case-control datasets of GWA data was carried out using IMPUTE and SNPTEST on HapMap. In total, 894 HapMap SNPs were successfully imputed in the interval between 130,051,729 bp and 131,225,253 bp using available SNP genotype data from GWA scans (225 SNPs). We verified the integrity of imputed data, where possible, by crosschecking the concordance of imputed genotypes with that of available Illumina SNP genotype data. Directly genotyped SNPs are denoted in blue; those imputed are shown in green.
To examine whether there is a relationship between SNP genotype and mRNA expression in lymphocytes and normal human cortex, we used publicly available data. We analyzed 90 CEU-derived Epstein-Barr virus-transformed lymphoblastoid cell lines using Sentrix Human-6 Expression BeadChips (Illumina). Online recovery of data was carried out using WGAViewer v1.25 Software 34, 35 . We analyzed 193 normal human cortex cells using Illumina HumanRef-seq-8 Expression BeadChip arrays 36 . Where SNPs genotyped in our study had not been typed, HapMap data were used to identify correlated SNPs in high LD (r 2 4 0.8). Differences in the distribution of levels of mRNA expression between SNP genotypes were compared using a Wilcoxon-type test for trend. Relationship between copy number change and mRNA expression at
